Physician profile
Rebecca E Smith
NPI 1124670641
$1,187.75
in general payments reported to CMS, 2019-2025
19 companies · $634 in 2025
The $634 reported for 2025 was more than what 79% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.60 · 2022: $69.92 · 2023: $177 · 2024: $295 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $327.55 | 2021-2025 | Lokelma, Farxiga |
| Nxstage Medical, INC. | $138.23 | 2025 | Nxstage System One, Liberty Select Cycler |
| Calliditas Therapeutics US INC. | $120.59 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $96.33 | 2025 | Velphoro |
| Amgen INC. | $83.62 | 2024-2025 | Krystexxa, Tavneos |
| Lilly USA, LLC | $58.38 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $50.75 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.31 | 2025 | Jardiance |
| Genzyme Corporation | $39.70 | 2025 | |
| Glaxosmithkline, LLC. | $35.76 | 2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $28.86 | 2022-2023 | |
| Medtronic, INC. | $28.52 | 2025 | Symplicity G3 |
| Vifor Pharma, INC. | $24.22 | 2024 | Veltassa |
| Novo Nordisk INC | $23.58 | 2025 | Ozempic |
| Daiichi Sankyo INC. | $19.33 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $17.97 | 2025 | Ultomiris |
| Verrica Pharmaceuticals INC. | $17.51 | 2023 | Ycanth |
| Otsuka America Pharmaceutical, INC. | $16.26 | 2024 | Jynarque |
| Novartis Pharmaceuticals Corporation | $15.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.